United Kingdom

Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

21 Sep 2018
Change (% chg)

$-1.28 (-3.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being... (more)


Beta: --
Market Cap(Mil.): $1,153.38
Shares Outstanding(Mil.): 35.93
Dividend: --
Yield (%): --


BRIEF-Biohaven Initiates Expanded Access Program For Sublingual BHV-0223

May 9 Biohaven Pharmaceutical Holding Company Ltd:

09 May 2018

Biohaven plunges as investors pit migraine data against Allergan's drug

Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.

26 Mar 2018

Biohaven tumbles as migraine drug efficacy fails to impress investors

March 26 Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.

26 Mar 2018

Earnings vs. Estimates